Beyond the Lab: Artificial Intelligence

Dear readers,

Welcome to our report on the latest advancements in artificial intelligence (AI) in drug discovery. This report explores how AI is transforming the development of new treatments, enhancing disease management and driving more personalised patient care.

Inside, you’ll discover how AI-driven platforms are accelerating the identification of therapeutic molecules and how AI-powered spatialomics is improving the clinical management of Barrett’s oesophagus with greater precision. We also highlight how digital twins are optimising treatment plans and improving clinical trial outcomes by simulating patient responses with remarkable accuracy.

Additionally, we examine how AI is advancing biotech, with companies harnessing big data and machine learning to identify new drug targets and predict patient responses more effectively. This report provides a comprehensive look at how AI is shaping the future of healthcare and drug discovery.

Featured experts: 

• Dr Boris Hayete – Senior Vice President of Computational Biology at Empress Therapeutics
• Dr Erik Martin – Castle Biosciences, Inc.
• Dr Rebecca Critchley-Thorne – Castle Biosciences, Inc.
• Dr Aaron Smith – Founder and ML Scientist at Unlearn.ai
• Dr Jennifer Bath – CEO and President of ImmunoPrecise Antibodies (IPA)
• Simon Turner – Partner at Sofinnova Partners
• Dr Venkat Reddy – Chief Scientific Officer of General Inception and President of Enable Medicine
• Dr Raminderpal Singh – Global Head of AI and GenAI Practice at 20/15 Visioneers
• Dr Remco Jan Geukes Foppen – Consultant at Regina Elena National Cancer Institute
• Vincenzo Gioia – AI Transition Manager – Independent Researcher
• Dr Carlos N Velez – Managing Partner at Lacerta Bio Inc.
• Alessio Zoccoli – Senior Data Scientist – Independent Researcher

Sincerely,

Dr Carrie Haslam

Editor

Drug Target Review